Status:
COMPLETED
Anthrax Vaccine Clinical Trials
Lead Sponsor:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Conditions:
Anthrax
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
This study will examine the recombinant, that is, produced by genetic engineering, protective antigen (rPA) that brings about antibodies to neutralize the anthrax toxin and that could therefore be pre...
Detailed Description
Anthrax is rarely encountered in the U.S. since the introduction of attenuated vaccines for cattle in the 1930's. A vaccine for humans, composed of a cell-free preparation absorbed onto alum, was lice...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA: Phase I
- Healthy 18 to 45 year-olds of either sex.
- EXCLUSION CRITERIA:
- Patients receiving chronic medication, are pregnant or intend to become pregnant during the study.
- Individuals who are HIV positive, have abnormal liver function, had anthrax, or received anthrax vaccine, have received or intend to receive an experimental vaccine or medication within 30 days of injection of the experimental anthrax vaccine.
Exclusion
Key Trial Info
Start Date :
September 8 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 25 2011
Estimated Enrollment :
93 Patients enrolled
Trial Details
Trial ID
NCT00114621
Start Date
September 8 2004
End Date
May 25 2011
Last Update
July 2 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Georgetown University
Washington D.C., District of Columbia, United States, 20007-2197
2
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892